Volume 2, Issue 2

2015pp 71—204

About the Cover

The cover for the issue of Oncoscience features Figure 2 (“SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma”) from Blanco et al.

News

Check’-ing DLBCL

Itziar Salaverria, Sílvia Beà

https://doi.org/10.18632/oncoscience.124pp 71—72

PDF Full-Text

Editorials

Functional polymorphisms in cancer

Divyansh Agarwal, Christos Hatzis, Lajos Pusztai

https://doi.org/10.18632/oncoscience.129pp 73—74

PDF Full-Text

TIC10/ONC201: a bend in the road to clinical development

Yoshimi Endo Greer, Stanley Lipkowitz

https://doi.org/10.18632/oncoscience.133pp 75—76

PDF Full-Text

BCC or not: Sufu keeps it in check

Wen-Chi Yin, Zhu Juan Li, Chi-chung Hui

https://doi.org/10.18632/oncoscience.134pp 77—78

PDF Full-Text

Fighting Neuroblastomas with NBAT1

Gaurav Kumar Pandey, Chandrasekhar Kanduri

https://doi.org/10.18632/oncoscience.126pp 79—80

PDF Full-Text

Reviews

Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies

Kimryn W. Rathmell, Fengju Chen, Chad J. Creighton

https://doi.org/10.18632/oncoscience.130pp 81—90

View Abstract PDF Full-Text

Research Perspectives

Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials

Miguel López-Lázaro

https://doi.org/10.18632/oncoscience.132pp 91—98

PDF Full-Text

MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments

Mariska Miranda, Esdy Rozali, Kum Kum Khanna, Fares Al-Ejeh

https://doi.org/10.18632/oncoscience.135pp 99—101

PDF Full-Text

SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma

Víctor M. Blanco, Richard Curry, Xiaoyang Qi

https://doi.org/10.18632/oncoscience.122pp 102—110

PDF Full-Text

Research Papers

Genistein exerts anti-leukemic effects on genetically different acute myeloid leukemia cell lines by inhibiting protein synthesis and cell proliferation while inducing apoptosis – molecular insights from an iTRAQ™ quantitative proteomics study

Karthik Narasimhan, Yew Mun Lee, Teck Kwang Lim, Sarah Alexandra Port, Jin-Hua Han, Chien-Shing Chen, Qingsong Lin

https://doi.org/10.18632/oncoscience.120pp 111—124

View Abstract PDF Full-Text

RAS mutations vary between lesions in synchronous primary Colorectal Cancer: Testing only one lesion is not sufficient to guide anti-EGFR treatment decisions.

Mariana Petaccia de Macedo, Fernanda Machado de Melo, Júlia da Silva Ribeiro, Celso Abdon Lopes de Mello, Maria Dirlei Ferreira de Souza Begnami, Fernando Augusto Soares, Dirce Maria Carraro, Isabela Werneck da Cunha

https://doi.org/10.18632/oncoscience.118pp 125—130

View Abstract PDF Full-Text

Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival

Esther Martínez-Martínez, Irene Gómez, Paloma Martín, Antonio Sánchez, Laura Román, Eva Tejerina, Félix Bonilla, Antonio García Merino, Antonio García de Herreros, Mariano Provencio, Jose M. García

https://doi.org/10.18632/oncoscience.119pp 131—141

View Abstract PDF Full-Text

TR4 nuclear receptor enhances prostate cancer initiation via altering the stem cell population and EMT signals in the PPARG-deleted prostate cells

Shin-Jen Lin, Dong-Rong Yang, Nancy Wang, Ming Jiang, Hiroshi Miyamoto, Gonghui Li, Chawnshang Chang

https://doi.org/10.18632/oncoscience.121pp 142—150

View Abstract PDF Full-Text

Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma

Edward Sanders, Svenja Diehl

https://doi.org/10.18632/oncoscience.128pp 151—186

View Abstract PDF Full-Text

Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations

Jorge Galvez Silva, Fernando F. Corrales-Medina, Ossama M. Maher, Nizar Tannir, Winston W. Huh, Michael E. Rytting, Vivek Subbiah

https://doi.org/10.18632/oncoscience.131pp 187—192

View Abstract PDF Full-Text

Versican is a potential therapeutic target in docetaxel-resistant prostate cancer

Naoko Arichi, Yozo Mitsui, Miho Hiraki, Sigenobu Nakamura, Takeo Hiraoka, Masahiro Sumura, Hiroshi Hirata, Yuichiro Tanaka, Rajvir Dahiya, Hiroaki Yasumoto, Hiroaki Shiina

https://doi.org/10.18632/oncoscience.136pp 193—204

View Abstract PDF Full-Text